
Magnesium for Depression
Does Magnesium Help With Depression?
If you feel sad, tired, and cranky, your doctor may suggest magnesium for depression. "We think of magnesium as just a trace mineral, but it's involved in hundreds of functions in the body, some of which impact mood," says James Greenblatt, MD, an integrative psychiatrist in Auburndale, Massachusetts, and an assistant clinical professor of psychiatry at Tufts University School of Medicine in Boston.
Research has shown that magnesium can be another powerful tool in your toolbox to treat depression. A 2023 review of seven clinical trials found that magnesium supplements significantly improved symptoms of depression. "Magnesium alone is rarely enough to treat depression, but when I've used it in patients, along with other treatments like talk therapy and antidepressants, I've found that it helps," explains Greenblatt.
There may be other reasons why magnesium helps to improve depression, too. One very small study published in Medical Research Archives found that people who took a daily gram of magnesium for two weeks reported improvements in sleep quality. "If you're well rested, you're better able to manage your mood and stress levels," says Greenblatt.
Magnesium Deficiency and Depression
It's thought that as many as half of all Americans may be low in magnesium, a nutrient that helps to regulate your muscles and nerves, manage your blood pressure and blood sugar, and make protein, bone, and DNA.
If your body doesn't have enough magnesium, it can put you at risk of mental health conditions like depression and anxiety. A 2019 study published in the journal Nutrients found that people with low blood levels of magnesium were more likely to have symptoms of depression. "Magnesium itself increases GABA, a brain chemical that helps you feel calm," explains Suruchi Chandra, MD, an integrative psychiatrist in Bethesda, Maryland. "It works in a very similar way to anti-anxiety medications such as alprazolam (Xanax)."
Magnesium does other things, too. It regulates other brain chemicals, such as glutamate and serotonin, that keep you calm and in a good mood, said Greenblatt. It also works indirectly to lower levels of stress hormones such as cortisol in your body. "It helps to control the release of ACTH, a hormone that stimulates the release of cortisol from your adrenal glands," Greenblatt explains.
There are a couple of common reasons why people may be low in magnesium. "The vegetables we eat now don't have the same levels of nutrients such as magnesium as they did one hundred years ago," says Greenblatt.
And many of us walk around chronically stressed – and stress has been shown to lower magnesium levels, adds Chandra. "This creates a snowball effect – the lower your magnesium levels are, the more stressed, anxious, and depressed you feel, which in turn depletes your body of magnesium even more," she explains.
You can get a blood test to check for a magnesium deficiency, but these aren't always reliable, says Chandra. "Magnesium is mostly stored in our bones and other organs like our brain, so even if your blood levels of magnesium are normal, you could still be deficient," she explains.
What Is the Best Magnesium for Depression?
There's no one best magnesium for depression. But magnesium glycinate for depression is very popular, says Greenblatt. This supplement is a combination of the mineral magnesium and the amino acid glycine. Glycine, which is also found in high-protein foods like meat and beans, has antioxidant properties, which may also help with depression. It comes in many forms, including pills, powders, and gummies.
There are other forms of magnesium, like magnesium oxide and magnesium-I-threonate. But Greenblatt recommends you try magnesium glycinate first. "Magnesium oxide isn't well absorbed by your body, and it can cause GI upset and diarrhea," he says.
Magnesium-I-threonate is better absorbed, but it tends to be more expensive than other forms, he adds. "With magnesium glycinate, more of the magnesium tends to be absorbed, and it usually has fewer GI-related side effects," says Greenblatt.
Magnesium for Depression Dosage
It's hard to know an exact dosage for magnesium for depression, as studies have looked at different amounts. The recommended dietary allowance (RDA) is 400-420 milligrams (mg) for adult men and 310-320 mg for women. But the National Institutes of Health recommends adults take no more than 350 mg of magnesium as a supplement every day. It's less than the RDA because most people will get more magnesium naturally through food and drinks.
People with depression may benefit from a slightly higher dose, of about 500 mg, says Greenblatt, as long as they are under a doctor's supervision. In these situations, break your magnesium dose up into two to three doses, which helps it be absorbed more easily into your bloodstream, he added, and take one of those doses before bed, to encourage and enhance sleep.
If you also take a vitamin D supplement, Greenblatt recommended that you take at least one of those doses at the same time. "Magnesium tends to enhance vitamin D absorption," he explains.
While magnesium is generally very safe, high amounts can cause side effects that include:
If you notice any of the above symptoms, let your doctor know right away. They may want to decrease your dose, or have you stop taking magnesium entirely.
Food Sources of Magnesium for Depression
You can also try to get magnesium from food. This is a very safe option, since your kidneys will get rid of any magnesium that you don't need through your pee. Some good food sources include:
Dark green leafy vegetables like spinach or swiss chard
Nuts like almonds, peanuts, and cashews
Seeds
Whole grains like brown rice
Oatmeal
Beans
Salmon
Beef
Poultry
Dark chocolate that's at least 70% cocoa
Milk and yogurt
Magnesium and Antidepressants
You may wonder if it's safe to take magnesium and antidepressants together. The answer is yes. "Generally, we see the best results if we use the two together," says Greenblatt. "While magnesium may be enough for someone with very mild depression, people who have moderate to severe depression will usually require prescription medications."
You also should never take magnesium supplements without first talking to your doctor, he stressed. In general, people shouldn't take magnesium if they already have kidney or heart disease. It can also interact with certain medications, such as:
Takeaways
If you have depression, you may benefit from taking a magnesium supplement. Research suggests it may improve your symptoms. Magnesium itself increases levels of GABA, a brain chemical that helps you feel calm. The best form of magnesium to use is magnesium glycinate. Just talk to your doctor before you take it, to make sure it's safe, and you are on the correct dose.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Real Madrid star Kylian Mbappe hospitalized with gastroenteritis at the Club World Cup
MIAMI (AP) — Real Madrid forward Kylian Mbappe has been hospitalized with an acute case of gastroenteritis, the Spanish club said Thursday. World Cup winner Mbappe missed Madrid's opening game at the Club World Cup against Saudi Arabian team Al Hilal in Miami on Wednesday because of a fever. Advertisement Coach Xabi Alonso said he hoped the France international would be available for the team's next game against Pachuca on Sunday. But his hospitalization casts doubt over what part he might be able to play in the monthlong tournament in the United States. 'Our player Kylian Mbappé is suffering from an acute case of gastroenteritis and has been admitted to hospital in order to undergo a series of tests and follow the appropriate course of treatment,' Madrid said in a statement. ___ James Robson is at ___ AP soccer: James Robson, The Associated Press
Yahoo
18 minutes ago
- Yahoo
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy fentanyl use1 Additional Indivior-funded research identified OUD treatment barriers in American Indian/Alaska Native (AI/AN) people who are often affected by higher drug overdose death rates compared to other racial and ethnic groups2-5 RICHMOND, Va., June 19, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) presented new findings this week at the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting. A post hoc analysis showed that patients with heavier fentanyl use experienced clinically meaningful improvements in opioid abstinence when treated with a 300 mg maintenance dose of SUBLOCADE, compared to the 100 mg dose. While the 300 mg dose did not demonstrate a statistically significant advantage over 100 mg for weekly abstinence—the study's primary endpoint—in the overall population with moderate to severe opioid use disorder (OUD), the results suggest that higher doses of SUBLOCADE may offer better outcomes for individuals with high levels of fentanyl use. "These findings offer additional evidence that the higher maintenance dose of SUBLOCADE is safe and may better support patients with intense fentanyl use patterns," said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. "We aim to provide clinicians with new data that can transform treatment strategies and support patients on their journey to recovery." In the Indivior-funded study, patients with OUD who engaged in high-risk opioid use—such as injection use, high opioid dose consumption, or fentanyl use—received two initial 300 mg injections of SUBLOCADE one week apart. They were then randomized to receive eight monthly maintenance doses of either 100 mg or 300 mg. Both dosing regimens led to significant reductions in opioid use: the average weekly use dropped sharply from over 40 instances at screening to fewer than 3 by Week 3, and this improvement was sustained through Week 38. Notably, no new safety concerns were identified with either the 100 mg or 300 mg maintenance doses. Indivior also funded research exploring OUD treatment access and outcomes in American Indian/Alaska Native (AI/AN) populations, which were presented at CPDD. AI/AN populations experience disproportionate rates of OUD, drug overdose, and gap in access to OUD care. A thematic analysis of focus group research on nine AI/AN advocates indicated that AI/AN people experience significant barriers to accessing medication for opioid use disorder (MOUD).4-8 Barriers include stigma, institutional challenges, and transitions of care for OUD, highlighting opportunities for culturally appropriate interactive education and institutional advancement.2 These focus group findings are illustrative and can be used to identify avenues for future work, although they may not be generalizable to the full population. In addition, a large multi-year longitudinal claims database analysis of more than 75,000 AI/AN patients with evidence of OUD showed differences in utilization of MOUD among those seeing Indian Health Services (IHS) vs. non-IHS providers. The majority of patients (73.1%) saw non-IHS providers. Patients treated with any form of MOUD had lower all-cause emergency department vs. those who were not treated with MOUD, highlighting the need for further research to understand MOUD utilization among AI/AN. "The collective evidence from these presentations highlights prominent barriers to effective care and helps map out appropriate treatment approaches for individuals with OUD in challenging treatment settings," said Heidbreder. "Indivior focuses its scientific, treatment, and policy efforts on helping patients access the medications and support they need to recover." Key Abstracts Presented at CPDD: Higher Exposures with 300-Mg Buprenorphine Extended-Release (BUP-XR) Increased the Proportion of Responders Among Opioid Use Disorder (OUD) Patients with Heavy Fentanyl Use Barriers to and Facilitators of Medication Treatment for Opioid Use Disorder Identified by American Indian/Alaska Native Advocates Utilization of Medications for Opioid Use Disorder (MOUD) and Patient Profiles Amongst American Indian/Alaska Native Managing Opioid Use Disorder (OUD) Polysubstance Use in Treatment for Opioid Use Disorder: Opioid Abstinence and Alternative Substance Use Clinical Outcomes and Recovery in Adults with Opioid Use Disorder: Long-term Treatment with Long- acting Injectable Buprenorphine under Real-World Conditions Severity and Symptomatology of Opioid Use Disorder (OUD) Among Individuals Reporting Pain Reliever Use, Pain Reliever Misuse, and/or Heroin Use: A Cross-sectional Analysis of the 2021 and 2022 National Survey on Drug Use and Health Disclosure: This press release has been issued by Indivior Inc. and the content has not been approved or authorized by the College on Problems of Drug Dependence. About SUBLOCADE® SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. HIGHLIGHTED SAFETY INFORMATION WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously. Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements. CONTRAINDICATIONS Hypersensitivity to buprenorphine or any other ingredients in SUBLOCADE. WARNINGS AND PRECAUTIONS Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration and necrosis. Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately. Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to and during treatment. Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patients have tolerated transmucosal buprenorphine before injecting SUBLOCADE. Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect. ADVERSE REACTIONS Adverse reactions commonly associated with SUBLOCADE (in ≥5% of subjects) were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain. For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit About Opioid Use Disorder (OUD) Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences. OUD may affect the parts of the brain that are necessary for life-sustaining functions. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting Higher Exposures with 300-Mg Buprenorphine Extended-Release (BUP-XR) Increased the Proportion of Responders Among Opioid Use Disorder (OUD) Patients with Heavy Fentanyl Use [Late Breaking Oral Sessions]. CPDD Annual Scientific Meeting, June 15, 2025. Barriers To and Facilitators Of Medication Treatment for Opioid Use Disorder Identified by American Indian/Alaska Native Advocates [Oral Session: Expanding SUD interventions across populations]. CPDD Annual Scientific Meeting, June 17, 2025. Utilization of Medications for Opioid Use Disorder (MOUD) and Patient Profiles amongst American Indian/Alaska Native Managing Opioid Use Disorder (OUD) [Poster Session 1]. CPDD Annual Scientific Meeting, June 15, 2025. Indian Health Service. Disparities. 2019. Retrieved from Accessed: 16 May 2024. Centers for Disease Control and Prevention, National Center for Health Statistics (2024). Rate of National Drug Overdose Deaths, By Demographic. Available at: statistics/overdose-death-rates. Accessed: 6 Jun 2024. Soto C, et al. (2022). International Journal of Environmental Research and Public Health, 19(5), 2974. doi:10.3390/ijerph19052974 Krawczyk N, et al. . Drug Alcohol Depend. 2021 Mar 1;220:108512. doi: 10.1016/ Mpofu, E, et al.. (2021). Addictive Behaviors, 114, 106743. doi:10.1016/ View original content to download multimedia: SOURCE Indivior PLC Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting
DURHAM, N.C., June 19, 2025 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that four abstracts describing efficacy and safety results from Satsuma's Phase 3 clinical study program were selected for presentation at the American Headache Society's (AHS) 67th Annual Scientific Meeting. The 2025 meeting will be held at the Minneapolis Convention Center Minneapolis, MN, from Thursday, June 19 to Sunday, June 22, 2025, including the option of participants attending virtually. Full abstracts are now available on the AHS website and will be published in the journal Headache®. Poster Presentation Details: Title: DHE Plasma Concentration and Clinical Response Relationship – An In-Office PK-PD Study Presenter: Detlef Albrecht, MD Poster: P-305 Date: Friday, June 20, 2025 Time: 5:00 PM – 6:15 PM CT (6:00 PM – 7:15 PM ET) Title: Strong CYP3A4 Inhibitor Itraconazole Does Not Cause Clinically Relevant Interactions with STS101 (Nasal Dihydroergotamine Powder) Presenter: Detlef Albrecht, MD Poster: P-307 Date: Friday, June 20, 2025 Time: 5:00 PM – 6:15 PM CT (6:00 PM – 7:15 PM ET) Title: STS101 Use Reduces Migraine Frequency Over Time Presenter: Stewart Tepper, MD Poster: P-309 Date: Friday, June 20, 2025 Time: 5:00 PM – 6:15 PM CT (6:00 PM – 7:15 PM ET) Title: STS101 (Dihydroergotamine Nasal Powder) Shows Benefit on the Resolution of Cardinal Migraine Symptoms Photophobia, Phonophobia, and Nausea: Results from the Long-Term Phase 3 Open-Label ASCEND Study Presenter: Amaal J. Starling, MD Poster: P-310 Date: Thursday, June 19, 2025 Time: 6:00 PM – 7:30 PM CT (7:00 PM – 8:30 PM ET) About Satsuma and STS101 Satsuma Pharmaceuticals, a wholly owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), is a late-stage biopharmaceutical company that recently received regulatory approval from the U.S. Food and Drug Administration for STS101, with the approved name Atzumi™ (Dihydroergotamine) nasal powder. For more information, please visit Satsuma is headquartered in Research Triangle Park, North Carolina. About SNBL Shin Nippon Biomedical Laboratories, Ltd. ("SNBL") (TSE:2395) is a listed nonclinical contract research organization (CRO) that was founded in Kagoshima, Japan, in 1957. Based on its corporate philosophy of "Committed to the environment, life, and people", and with a proven track record of accomplishment as the oldest and most established Japanese nonclinical CRO, SNBL is proud to offer a comprehensive portfolio of services and solutions for drug discovery and development for pharmaceutical companies, biotech ventures, universities, and research institutions both in Japan and overseas. The SNBL's Translational Research business engages in drug discovery, with the focus on business development and out-licensing of its proprietary intranasal drug delivery technologies and intranasal devices. For further information, please visit Cautionary Note on Forward-Looking Statements Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding SNBL's future business, future position and results of operations, including estimates, forecasts, targets and plans for SNBL. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could" "anticipates", "estimates", "projects" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding SNBL's business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of product candidates; the impact of health crises such as the coronavirus pandemic on SNBL and its clients and suppliers, including foreign governments in countries in which SNBL operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to SNBL's operations and the timing of any such divestment(s); and other factors identified in SNBL's most recent securities report ("YukaShoken Houkokusho") and SNBL's other reports filed with the Financial Services Agency, available on SNBL's website at: or at SNBL does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or related stock exchange rule. Past performance is not an indicator of future results and the results or statements of SNBL in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of SNBL's future results. Medical information This press release contains information about product candidates that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Inquiries:Satsuma Pharmaceuticals, Inc.E-mail: info@ View original content to download multimedia: SOURCE Satsuma Pharmaceuticals, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data